DNMT3A Mutational Status Affects the Results of Dose-Escalated Induction Therapy in Acute Myelogenous Leukemia.

@article{Sehgal2015DNMT3AMS,
  title={DNMT3A Mutational Status Affects the Results of Dose-Escalated Induction Therapy in Acute Myelogenous Leukemia.},
  author={Alison Sehgal and Phyllis A. Gimotty and Jianhua Zhao and Jing-Mei Hsu and Robert D. Daber and Jennifer J D Morrissette and Selina M. Luger and Alison W. Loren and Martin P. Carroll},
  journal={Clinical cancer research : an official journal of the American Association for Cancer Research},
  year={2015},
  volume={21 7},
  pages={1614-20}
}
PURPOSE DNA methyltransferase 3A (DNMT3A) is one of the commonly mutated genes in acute myelogenous leukemia (AML). Reports on the prognostic significance of DNMT3A mutations have been inconsistent, and most of the data are available only for patients 60 years of age or younger. We hypothesized that this inconsistency is due to an interaction between the dose of anthracycline used in induction therapy and DNMT3A status. We studied whether patients with DNMT3A-mutated AML treated with standard… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 17 extracted citations

Clinical and biological implications of IDH1/2 in acute myeloid leukemia with DNMT3Amut

Cancer management and research • 2018
View 9 Excerpts
Highly Influenced

Acute myeloid leukaemia genomics.

British journal of haematology • 2017
View 1 Excerpt

DNMT3A in Leukemia.

Cold Spring Harbor perspectives in medicine • 2017
View 1 Excerpt

Acute Myeloid Leukemia: A Concise Review

Journal of clinical medicine • 2016
View 1 Excerpt

Acute myeloid leukaemia

Nature Reviews Disease Primers • 2016

Similar Papers

Loading similar papers…